Billionaire Boys Club Member Forum (BBCMF)

[mick]

i like it! AIDS STUDY? Strategic Health Resources LLC Retained by Cannabis Science for Government Relations to Identify Opportunities and Collaborative Research

http://finance.yahoo.com/news/strategic-health-resources-llc-retained-175400452.html

Press Release: Cannabis Science, Inc. – 1 hour 18 minutes ago


[-chart]ichart.finance.yahoo.com/t?s=cbis&lang=en-US®ion=us[/chart]

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--

Cannabis Science, Inc. (CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce Strategic Health Resources LLC, an Arlington, VA-based biomedical and health systems consulting firm, has been retained by Cannabis Science (CS) to provide consulting services that

identify opportunities and collaborative research and development agreements for the biomedical sector of CS and develops support for biomedical research, specifically as that research relates to long term infectious disease mitigation, PTSD and TBI.

SHR will also provide non-legal guidance on regulations and policies that impact the development of the firm’s biomedical products.

SHR was founded in 2007 by senior congressional staff, including its principal Rick Blake, who has worked on health policy and disease prevention issues for over two decades. Rick formerly served as the senior health policy advisor to Cong.

Ed Towns, (NY-10th) for work related to the Subcommittee on Health, the Energy and Commerce Committee and the Committee on Oversight. In these capacities, he wrote numerous congressional health bills and held over a dozen health hearings.

About CS-TATI-1

Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant.

Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies.

Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).



[-chart]charts.stockscores.com/chart.asp?TickerSymbol=CBIS&TimeRange=180&Interval=d&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=830&ChartHeight=500&LogScale=None&Band=DC&avgType1=EMA&movAvg1=&avgType2=TMA&movAvg2=&Indicator1=MACD&Indicator2=StochRSI&Indicator3=SStoch&Indicator4=CVolatility&endDate=&CompareWith=[/chart]



[-chart]stockcharts.com/def/servlet/SharpChartv05.ServletDriver?chart=CBIS,pstgdanrbo[pa][d][f1!2!!!2!20]&pnf=y[/chart]

About Cannabis Science, Inc.

Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.

Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur.

Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.


..Contact:.
.Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
[e-mail]
www.cannabisscience.com
or
Robert Kane
VP Investor Relations
1-561-234-6929
[e-mail]
[e-mail]
www.cannabisscience.com